MeSH tree: D12.776.124.486.485.114.224.060.782
Aromatase inhibitors (AIs) are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen production, AIs accelerate bone ...
Feb 10, 2026
0
6
A new international study published in Osteoporosis International and led by Monash's Center for Medicine Use and Safety (CMUS) has investigated the risks of a second hip fracture, subsequent fractures, and death in people ...
Dec 8, 2025
0
14
People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society's annual meeting in San ...
Jul 12, 2025
0
30
The International Osteoporosis Foundation (IOF) Bone and Cancer Working Group has released a comprehensive review detailing the often under-recognized impact of modern anti-cancer treatments on bone health.
Jun 23, 2025
0
16
Certain medications used in the treatment of bone conditions, particularly when combined with corticosteroids, may significantly increase the risk of a rare but serious jaw disease. This finding comes from a study by the ...
Jun 3, 2025
0
50
Science and society collaboration is essential for scientific progress, especially in the health and biomedical fields where basic researchers, clinicians and patients are involved, as shown by the initial results of D-BIOMARK. ...
May 16, 2025
0
63
For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE) compared with oral bisphosphonates, ...
Jan 7, 2025
0
14
For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with worsening CKD stage, according to a study published online Nov. 19 in the Annals of Internal Medicine.
Nov 20, 2024
0
16
Bisphosphonates are the recommended first-line treatment in post-menopausal osteoporosis, with denosumab recommended second-line. Based on the length of clinical trials for bisphosphonates, these drugs are usually prescribed ...
Jun 12, 2024
0
36
Worldwide, it is estimated that one in five men over the age of 50 years will experience an osteoporotic fracture in their remaining lifetime, and the number of hip fractures in men is expected to rise by approximately 310% ...
Mar 25, 2024
0
69
